Skip to content

Author

I. Attili

We have 2 of 113 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Neoadjuvant durvalumab plus chemotherapy in resectable or borderline resectable non-small-cell lung cancer: the phase 2 MDT-BRIDGE trial.

The phase 2 MDT-BRIDGE study is investigating perioperative durvalumab plus neoadjuvant chemotherapy (AEGEAN regimen) in resectable and borderline resectable non-small-cell lung cancer and chemoradiotherapy (CRT) followed by consolidation durvalumab (PACIFIC regimen) in patients who become unresectable after neoadjuvan...

Martin Reck, E. Nadal, C. Gay et al. · 0 citations
Review Open access Sep 2026

p53 Co-mutations in EGFR-mutant NSCLC: biological insight and therapeutic implications.

The biological function of p53, its role in EGFR-mutant lung cancer, and the implications for current and future therapies are discussed, and a timely and cohesive synthesis of a rapidly evolving field is offered.

J. Etessami, I. Attili, P. T. Aliaga et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.